Working... Menu
Trial record 4 of 4 for:    Parasomnias | ( Map: Chile )

Efficacy and Safety of Eplivanserin Treatment for Sleep Maintenance Insomnia Followed by Optional Extension up to 1 Year (EPLILONG)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00253903
Recruitment Status : Completed
First Posted : November 15, 2005
Last Update Posted : November 30, 2010
Information provided by:

Brief Summary:
The purpose of the study is to assess efficacy and safety of eplivanserin in the population of patients complaining of sleep maintenance insomnia. The patients suffering from that condition frequently wake up during the night, their sleep is nonrestorative and they suffer from a significant distress or impairment in their daily activities consecutive to insomnia.

Condition or disease Intervention/treatment Phase
Sleep Initiation and Maintenance Disorders Insomnia Drug: eplivanserin (SR46349) Drug: placebo Phase 3

Detailed Description:

The study is being conducted worldwide.

It consists of 4 segments:

  • Segment A: 7-day run-in (screening)
  • Segment B: 12-week double blind treatment
  • Segment C: 40-week open treatment extension
  • Segment D: 2-week run-out period

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1155 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Efficacy and Safety of Eplivanserin 5mg/Day on Sleep Maintenance Insomnia: a 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study Followed by an Open Treatment Phase Extension With Eplivanserin for a 40-week Period
Study Start Date : November 2005
Actual Primary Completion Date : November 2007
Actual Study Completion Date : September 2008

Arm Intervention/treatment
Experimental: 1
5 mg/day
Drug: eplivanserin (SR46349)
oral administration

Placebo Comparator: 2 Drug: placebo
oral administration

Primary Outcome Measures :
  1. Change from baseline of the mean pr-WASO (wake time after sleep onset using patient's sleep questionnaire) [ Time Frame: at week 12 ]

Secondary Outcome Measures :
  1. Change from baseline of the mean of the FOSQ items 1 and 2 (concentration/memory) [ Time Frame: at week 12 ]
  2. Change from baseline of the mean of the FOSQ items 4 and 10 (hobby/work) [ Time Frame: at week 12 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Out patients
  • Each patient must have primary insomnia in accordance with DSM-IV-TR-Axis I criteria
  • Based on patient's information, the patient has spent at least 6.5 hours and not more than 9.0 hours, in bed, each night, over the preceding two weeks.
  • Based on patient's information, the patient must complain of at least one hour of wakefulness after sleep onset for at least 3 nights per week over the preceding month
  • Patient must report impact daytime functioning associated with sleep maintenance insomnia as measured by question 3 of Insomnia Severity Index at screening visit and randomization visit.

Exclusion Criteria:

  • Females who are lactating or pregnant
  • Woman of childbearing potential with a positive serum beta human chorionic gonadotropin pregnancy test at screening and not using an acceptable form of contraception
  • Patients presenting with acute or chronic pain resulting in insomnia
  • Patients with history of epilepsy or seizures
  • Consumption of xanthine containing beverage (i.e. tea, coffee, or cola) comprising more than 5 glasses/day
  • Evidence of any clinically significant, severe, or unstable acute or chronically progressive medical or surgical disorder which may affect patient safety
  • BMI >32
  • Acute or chronic pain resulting in insomnia
  • Patients with current psychiatric disorders according to DSM-IV-TR criteria, mental retardation, or dementia
  • Clinically significant and abnormal EKG (QTc interval >500 msec)
  • Positive for hepatitis B or C
  • Serious head injury or stroke within 1 year
  • Use of OTC medications such as valerian root, kava, melatonin, St. John's Wort, or alluna; prescription sleep medications or anxiolytics within 1 week or 5 half-lives
  • Participation in another trial within two month before the screening visit
  • Use of any substance with psychotropic effects or properties known to affect sleep/wake
  • Unable to complete the study questionnaires
  • Night shift workers, and individuals who nap 3 or more times per week over the preceding month
  • History of:

    • Primary hypersomnia
    • Narcolepsy
    • Breathing-related sleep disorder (such as sleep apnea)
    • Circadian rhythm sleep disorder
    • Parasomnia (somnambulism)
    • Dyssomnia (such as periodic leg movements)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00253903

Layout table for location information
United States, New Jersey
Sanofi-Aventis Administrative Office
Bridgewater, New Jersey, United States, 08807
Sanofi-Aventis Administrative Office
Buenos Aires, Argentina
Australia, New South Wales
Sanofi-Aventis Administrative Office
Macquarie Park, New South Wales, Australia
Sanofi-Aventis Administrative Office
Vienna, Austria
Canada, Quebec
Sanofi-Aventis Administrative Office
Laval, Quebec, Canada
Sanofi-Aventis Administrative Office
Santiago, Chile
Czech Republic
Sanofi-Aventis Administrative Office
Praha, Czech Republic
Sanofi-Aventis Administrative Office
Helsinki, Finland
Sanofi-Aventis Administrative Office
Paris, France
Sanofi-Aventis Administrative Office
Berlin, Germany
Sanofi-Aventis Administrative Office
Mexico, Mexico
Sanofi-Aventis Administrative Office
Gouda, Netherlands
Sanofi-Aventis Administrative Office
Barcelona, Spain
United Kingdom
Sanofi-Aventis Administrative Office
Guildford, United Kingdom
Sponsors and Collaborators
Layout table for investigator information
Study Director: ICD CSD Sanofi

Layout table for additonal information
Responsible Party: ICD Study Director, sanofi-aventis Identifier: NCT00253903     History of Changes
Other Study ID Numbers: LTE6262
EucraCT: 2005-003082-16
First Posted: November 15, 2005    Key Record Dates
Last Update Posted: November 30, 2010
Last Verified: November 2010

Keywords provided by Sanofi:
Primary Insomnia
Early Awakening
Chronic Insomnia

Additional relevant MeSH terms:
Layout table for MeSH terms
Sleep Disorders, Intrinsic
Sleep Wake Disorders
Sleep Initiation and Maintenance Disorders
Nervous System Diseases
Mental Disorders
SR 46349B
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Platelet Aggregation Inhibitors
Serotonin Antagonists
Serotonin Agents
Neurotransmitter Agents
Physiological Effects of Drugs